Clinical trials: Skin Diseases, Papulosquamous
Psoriasis
MAP Study: Methotrexate and Adalimumab in Psoriasis
Assess the efficacy and safety of ADA compared to ADA/MTX in patient with Psoriasis. Compare Anti-ADA antibody formation and serum ADA levels in patients on ADA compared with those on combination ADA and MTX.
- Trial name
- MAP (NCT03217734)
- Testing
- Adalimumab, Methotrexate
- Where
- 4 sites in United States
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Jeffrey J Crowley MD
Psoriasis, Obesity
Pilot Study Characterizing Adipose Tissue Leukocytes by Flow Cytometry/Microscopy in Lean, Obese and Psoriatic Subjects
Obesity is an insulin resistance-associated metabolic disorder which is a hallmark of and risk factor for type 2 diabetes and the metabolic syndrome, often linked to cardiovascular disease, certain cancers and inflammatory…
- Trial name
- NCT01856647
- Testing
- Adipose tissue biopsy (fat biopsy)
- Where
- United States
- Volunteers
- 1 people, healthy volunteers welcome
- Sponsor
- Rockefeller University
Psoriasis
A Study to Evaluate Efalizumab in Adults With Plaque Psoriasis, Including Those Who Are Receiving Concomitant Antipsoriatic Therapies
This is a Phase IIIb, open label, uncontrolled, multicenter study designed to evaluate the safety and tolerability of 12 weeks of subcutaneously administered efalizumab in subjects with moderate to severe plaque psoriasis who are…
- Trial name
- NCT00338143
- Testing
- efalizumab
- Volunteers
- 1,200 people
- Sponsor
- Genentech, Inc.
Psoriasis, Metabolic Syndrome
Peds Metabolic Syndrome in Psoriasis
The objective of this study is to assess whether there is an increased risk of the metabolic syndrome in children with psoriasis compared to children without psoriasis.
- Trial name
- NCT00930592
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- Tufts Medical Center
Arthritis, Psoriatic
A Study of RO5310074 in Patients With Psoriatic Arthritis
This randomized, double-blind. placebo-controlled study will assess the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple doses of RO5310074 in patients with psoriatic arthritis who have or have had an…
- Trial name
- NCT01199809
- Testing
- RO5310074
- Where
- 9 sites in United States, Australia and 1 more
- Volunteers
- 19 people
- Sponsor
- Hoffmann-La Roche
Psoriasis
Developing A Validated Measure of the Impact of Psoriasis on Chronic Quality of Life
Objective of the study is to create and validate Chronic Quality of Life (CQOL) index that explores habits, career paths and other life choices psoriasis patients make as a result of coping with their disease that may not be…
- Trial name
- NCT00823914
- Where
- United States
- Volunteers
- 116 people
- Sponsor
- Massachusetts General Hospital
Psoriasis
Comparative Study of CMAB015 and Secukinumab for Patients With Moderate to Severe Plaque Psoriasis
The goal of this trial is to assess whether the efficacy of CMAB015 is similar to that of Secukinumab in patients with moderate-severe chronic plaque psoriasis.
- Trial name
- NCT06398652
- Testing
- CMAB015, Secukinumab
- Where
- China
- Volunteers
- 336 people
- Sponsor
- Taizhou Mabtech Pharmaceutical Co.,Ltd
Psoriatic Arthritis
Multicentre ObservatioNal Initiative in Treat to Target Outcomes in Psoriatic Arthritis
MONITOR is a cohort study recruiting patients with a new diagnosis of psoriatic arthritis (PsA) which will establish outcomes using a pragmatic feasible 'treat to target' approach in a real-life clinic population.
- Trial name
- MONITOR (NCT03531073)
- Testing
- Methotrexate
- Where
- United Kingdom
- Volunteers
- 446 people
- Sponsor
- University of Oxford
Psoriasis
A Registry of Patients With Moderate to Severe Plaque Psoriasis
The main purpose of the current study will be to provide real - world evidence regarding the safety and effectiveness of secukinumab in the management of patients with moderate to severe chronic plaque psoriasis.
- Trial name
- PURE (NCT02786186)
- Testing
- Secikinumab
- Where
- 13 sites in Canada
- Volunteers
- 2,376 people
- Sponsor
- Novartis Pharmaceuticals
Psoriasis
A Study to Evaluate Raptiva in Subjects With Chronic Moderate or Worse Plaque Psoriasis Who Have Had an Inadequate Response to an Anti-TNF Agent
This is a Phase IV open-label study to evaluate the efficacy and safety of SC efalizumab in adult subjects (18 years of age and older) with chronic moderate or worse plaque psoriasis who have had an inadequate response to…
- Trial name
- NCT00336973
- Testing
- efalizumab
- Volunteers
- 73 people
- Sponsor
- Genentech, Inc.
Psoriasis
Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of CC-90006 in Subjects With Mild to Moderate Plaque-type Psoriasis
This is a multi-center, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and immunogenicity of CC-90006 following administration of multiple…
- Trial name
- NCT03337022
- Testing
- CC-90006
- Where
- 4 sites in United States, Canada
- Volunteers
- 34 people
- Sponsor
- Celgene
Oral Lichen Planus
Effectiveness of a Sodium Hyaluronate 0.01% and Sh-Oligopeptide-85 SP Mouthwash for the Treatment of Symptomatic Oral Lichen Planus
Annex 1. Patient Information and Informed Consent for the Study Study Title: Effectiveness of a sodium hyaluronate 0.01% and Sh-Oligopeptide-85 SP mouthwash for the treatment of symptomatic oral lichen planus: a randomized…
- Trial name
- NCT07280442
- Testing
- Sodium hyaluronate 0.01% and Sh-Oligopeptide-85 SP Mouthwash
- Where
- Spain
- Volunteers
- 40 people
- Sponsor
- Universidad Complutense de Madrid
Carpal Tunnel Syndrome, Psoriatic Arthritis
Carpal Tunnel Syndrome in Patients With Psoriatic Arthritis; Ultrasonography and Magnetic Resonance Imaging Findings
This study aimed to investigate relationship between CTS diagnosis with electrodiagnostic studies and median nerve's cross-sectional area measered by US and MRI in PsA patients.
- Trial name
- NCT05086042
- Testing
- Ultrasonography, Magnetic resonance imaging
- Where
- Turkey (Türkiye)
- Volunteers
- 67 people, healthy volunteers welcome
- Sponsor
- Selcuk University
Oral Lichen Planus, Oral Leukoplakia
Evaluation of Artificial Intelligence in Diagnosis and Risk Assessment of Oral Potentially Malignant Disorders
Oral potentially malignant disorders (OPMDs) are mucosal lesions that carry a risk of malignant transformation into oral cancer.
- Conditions
- Oral Lichen Planus, Oral Leukoplakia, Traumatic Ulcer of Oral Mucosa, Erythroleukoplakia of Mouth
- Trial name
- NCT07318922
- Testing
- Toluidine blue staining of the lesion and cytological smears
- Volunteers
- 120 people
- Sponsor
- Ain Shams University
Psoriatic Arthritis
PsA Secukinumab XCT Structural Progression Study
Psoriatic arthritis is related with chronic inflammation and progressive radiographic damages, and it in turn lead to disability and loss in function-ability.
- Trial name
- NCT03623867
- Testing
- Secukinumab
- Where
- Hong Kong
- Volunteers
- 40 people
- Sponsor
- Chinese University of Hong Kong
Psoriasis
A Study to Evaluate Effectiveness and Safety of BMS-986322 in Participants With Moderate-to-Severe Psoriasis
The purpose of this study is to evaluate clinical effectiveness and safety of BMS-986322 in participants with moderate-to-severe psoriasis.
- Trial name
- NCT05730725
- Testing
- BMS-986322
- Where
- 35 sites in United States, Australia and 3 more
- Volunteers
- 109 people
- Sponsor
- Bristol-Myers Squibb
Seborrheic Dermatitis
Long-Term Safety of ARQ-154 Foam in Subjects With Seborrheic Dermatitis
This is an open-label, long-term safety study of roflumilast ARQ-154 foam 0.3% in subjects with seborrheic dermatitis involving up to 20% total Body Surface Area (BSA). Study was applied topically once daily for 52 weeks.
- Trial name
- NCT04445987
- Testing
- ARQ-154
- Where
- 39 sites in United States
- Volunteers
- 408 people
- Sponsor
- Arcutis Biotherapeutics, Inc.
Psoriasis, Psoriatic Arthritis
SystemIc iNflammation and Microvascular diSease PreventIon in psoRiatic diseasE
This is a single-label open-arm mechanistic clinical study recruiting patients with psoriasis or psoriatic arthritis with elevated cardiovascular risk.
- Conditions
- Psoriasis, Psoriatic Arthritis, Cardiovascular Risk Factor
- Trial name
- INSPIRE (NCT04417114)
- Testing
- Rosuvastatin
- Sponsor
- Brigham and Women's Hospital
Psoriasis
Utility of Squamous Cell Carcinoma Antigen (SCCA) in Psoriasis
Squamous Cell Carcinoma Antigen (SCCA) contributes to the pathogenesis of psoriasis by inhibiting cell apoptosis, exacerbating epidermal hyperplasia and skin inflammation.
- Trial name
- SCCAPSO (NCT04308616)
- Testing
- Blood samples
- Where
- France
- Volunteers
- 51 people
- Sponsor
- University Hospital, Tours
Psoriasis
Efficacy and Safety of Deucravacitinib Versus Placebo in Participants With Moderate-to-severe Scalp Psoriasis
The purpose of this study is to compare the efficacy and safety of deucravacitinib to placebo in participants with moderate-to-severe scalp psoriasis.
- Trial name
- NCT05478499
- Testing
- Deucravacitinib
- Where
- 29 sites in United States, France and 3 more
- Volunteers
- 154 people
- Sponsor
- Bristol-Myers Squibb
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.